Art. -Nr.: HY-13704

SN-38

(Synonyms: 7-Ethyl-10-hydroxycamptothecin)

79 Cited Publications

Kundenbewertung

Based on 79 publication(s) in Google Scholar

SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 can bind to RPL15. SN-38 inhibits DNA and RNA synthesis with IC₅₀s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.94%
CAS. Nr.: 86639-52-3
Formel: C₂₂H₂₀N₂O₅
Molecular Weight:392.40

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

SN-38 Chemical Structure

CAS. Nr.: 86639-52-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (79)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Topoisomerase I

Camptothecins

RPL15

Alle Topoisomerase Isoform-spezifische Produkte anzeigen :

Alle ADC Payloads Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against human 16HBE cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human 16HBE cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
A2780	IC₅₀	0.009 μM Compound: 3, SN38	Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
A498	GI₅₀	0.22 μM Compound: SN-38	Growth inhibition of human A498 cells by Cell-titer96 assay Growth inhibition of human A498 cells by Cell-titer96 assay	[PMID: 33492141]
A549	IC₅₀	16 nM Compound: SN-38	In Vitro cytotoxicity against human lung cancer cell line (A549) In Vitro cytotoxicity against human lung cancer cell line (A549)	[PMID: 11334569]
A549	IC₅₀	0.08 μM Compound: SN-38	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 18986807]
A549	IC₅₀	0.088 μM Compound: 5, SN-38	Antitumor activity against human A549/ATCC cells by SRB method Antitumor activity against human A549/ATCC cells by SRB method	[PMID: 19541483]
A549	IC₅₀	0.047 μM Compound: SN-38	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 21470864]
A549	IC₅₀	0.259 μM Compound: 5, SN-38	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 24529870]
A549	IC₅₀	2.72 nM Compound: 5, SN-38	Cytotoxicity against human A549 cells assessed as growth inhibition after 3 days by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 3 days by SRB assay	[PMID: 24529870]
A549	IC₅₀	1.62 nM Compound: SN-38	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30115492]
A549	IC₅₀	0.2 μM Compound: SN38	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 30169038]
A549	IC₅₀	6.6 μM Compound: SN-38	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
A549	IC₅₀	11 nM Compound: SN38	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
A549	IC₅₀	0.018 μM Compound: SN-38	Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
A549	IC₅₀	45.4 nM Compound: SN-38	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32679451]
A549	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against FR-negative human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against FR-negative human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
A549	IC₅₀	0.028 μM Compound: 1d; SN38	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
A549	IC₅₀	11.9 nM Compound: SN-38	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay	[PMID: 34963283]
A549	IC₅₀	3.8 nM Compound: SN-38	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 120 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 120 hrs by CCK-8 assay	[PMID: 34963283]
A549	IC₅₀	1.62 nM Compound: 14; SN-38	Cytotoxicity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
ACHN	GI₅₀	5.9 nM Compound: 4; SN-38	Antiproliferative activity against human ACHN cells after 48 hrs by SRB assay Antiproliferative activity against human ACHN cells after 48 hrs by SRB assay	[PMID: 30553626]
Bel-7402	IC₅₀	3.19 μM Compound: 7-Ethyl-10-hydroxycamptothecin (SN-38)	Inhibitory concentration against human Bel-7402 liver cancer cell line Inhibitory concentration against human Bel-7402 liver cancer cell line	[PMID: 15808456]
Bel-7402	IC₅₀	13 nM Compound: SN-38	In-vitro inhibitory concentration for human tumor BEL-7402 cell-line was determined using MTT assay after 3 days of incubation In-vitro inhibitory concentration for human tumor BEL-7402 cell-line was determined using MTT assay after 3 days of incubation	[PMID: 15913996]
Cancer cell lines	GI₅₀	0.066 μM Compound: SN-38	Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	0.066 μM Compound: SN-38	Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	0.066 μM Compound: SN-38	Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
CAPAN-1	IC₅₀	8 nM Compound: SN38	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
carcinoma cell line	IC₅₀	0.08 μM Compound: SN-38	Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460) Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460)	[PMID: 11563925]
CCD-841CoN	IC₅₀	4.98 μM Compound: 1d; SN38	Cytotoxicity against human CCD-841CoN cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human CCD-841CoN cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
COLO 205	IC₅₀	0.22 μM Compound: SN-38	Cytotoxicity against human COLO 205 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human COLO 205 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
COLO 205	IC₅₀	0.75 nM Compound: 2; SN38	Cytotoxicity against human COLO 205 cells incubated for 48 hrs by SRB assay Cytotoxicity against human COLO 205 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
DU-145	IC₅₀	0.013 μM Compound: SN-38	Antiproliferative activity against human DU145 prostate cell line Antiproliferative activity against human DU145 prostate cell line	[PMID: 10498216]
DU-145	IC₅₀	0.004 μM Compound: SN-38	Antiproliferative activity against human DU145 cells after 96 hrs Antiproliferative activity against human DU145 cells after 96 hrs	[PMID: 18276141]
DU-145	IC₅₀	30 nM Compound: SN-38	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 23578545]
DU-145	IC₅₀	0.11 μM Compound: SN-38	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 23622981]
DU-145	GI₅₀	4.3 nM Compound: 4; SN-38	Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay	[PMID: 30553626]
HCT-116	IC₅₀	0.007 μM Compound: 7-Ethyl-10-hydroxycamptothecin (SN-38)	Inhibitory concentration against human HCT116 colon cancer cell line Inhibitory concentration against human HCT116 colon cancer cell line	[PMID: 15808456]
HCT-116	IC₅₀	3.3 nM Compound: SN-38	In-vitro inhibitory concentration for human tumor HCT116 cell-line was determined using MTT assay after 3 days of incubation In-vitro inhibitory concentration for human tumor HCT116 cell-line was determined using MTT assay after 3 days of incubation	[PMID: 15913996]
HCT-116	IC₅₀	0.55 nM Compound: SN-38	Antiproliferative activity against human HCT116 cells after 3 days Antiproliferative activity against human HCT116 cells after 3 days	[PMID: 19254843]
HCT-116	IC₅₀	0.166 μM Compound: 5, SN-38	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 24529870]
HCT-116	IC₅₀	31 nM Compound: 5, SN-38	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 3 days by SRB assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 3 days by SRB assay	[PMID: 24529870]
HCT-116	IC₅₀	4.28 nM Compound: SN-38	Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay	[PMID: 25835359]
HCT-116	IC₅₀	0.78 nM Compound: SN-38	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 30115492]
HCT-116	GI₅₀	23 nM Compound: 4; SN-38	Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 30553626]
HCT-116	IC₅₀	<1 μM Compound: SN-38	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
HCT-116	IC₅₀	4 nM Compound: SN38	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
HCT-116	IC₅₀	0.01 μM Compound: SN-38	Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
HCT-116	IC₅₀	55.1 nM Compound: SN-38	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32679451]
HCT-116	GI₅₀	0.02 μM Compound: SN-38	Growth inhibition of human HCT-116 cells by Cell-titer96 assay Growth inhibition of human HCT-116 cells by Cell-titer96 assay	[PMID: 33492141]
HCT-116	IC₅₀	54.93 nM Compound: 2; SN38	Cytotoxicity against human HCT-116 cells incubated for 48 hrs by SRB assay Cytotoxicity against human HCT-116 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
HCT-116	IC₅₀	0.55 nM Compound: 14; SN-38	Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
HCT-15	IC₅₀	0.008 μM Compound: SN-38	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
HEK293	IC₅₀	360 μM Compound: SN-38	Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method	[PMID: 21030469]
HEK293	IC₅₀	<1 μM Compound: SN-38	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
HEK-293T	IC₅₀	14.2 nM Compound: SN-38	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay	[PMID: 34963283]
HeLa	IC₅₀	13.1 μM Compound: SN-38	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
HeLa	IC₅₀	0.145 μM Compound: SN-38	Cytotoxicity against human Hela assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human Hela assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
HeLa	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against FR-positive human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against FR-positive human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
HeLa	IC₅₀	>1 μM Compound: SN38	Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	349 nM Compound: SN38	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	22 nM Compound: 14; SN-38	Cytotoxicity against human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
Hep 3B2	GI₅₀	0.177 μM Compound: SN-38	Growth inhibition of human Hep3B cells by Cell-titer96 assay Growth inhibition of human Hep3B cells by Cell-titer96 assay	[PMID: 33492141]
HepG2	IC₅₀	0.48 μM Compound: SN38	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30600208]
HepG2	IC₅₀	480 nM Compound: 14; SN-38	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
HL-60	IC₅₀	19 nM Compound: SN-38	In-vitro inhibitory concentration for human tumor HL60 cell-line was determined using SRB assay after 3 days of incubation In-vitro inhibitory concentration for human tumor HL60 cell-line was determined using SRB assay after 3 days of incubation	[PMID: 15913996]
HL-60	IC₅₀	2.4 μM Compound: SN-38	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
HL-60	IC₅₀	0.002 μM Compound: 1d; SN38	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
HOC-21 cell line	IC₅₀	123.1 ng/mL Compound: 5	Tested in vitro for the inhibition of HOC-21(human ovarian cancer) cell line by MTT assay Tested in vitro for the inhibition of HOC-21(human ovarian cancer) cell line by MTT assay	[PMID: 7932525]
HOC-21 cell line	IC₅₀	41.2 ng/mL Compound: 5 (SN-38)	In vitro antitumor activity against HOC-21 (human ovarian cancer) cells. In vitro antitumor activity against HOC-21 (human ovarian cancer) cells.	[PMID: 9632364]
HT-29	IC₅₀	0.022 μM Compound: SN-38	Antiproliferative activity against human HT-29 colon cell line Antiproliferative activity against human HT-29 colon cell line	[PMID: 10498216]
HT-29	IC₅₀	27.3 nM Compound: 3 (SN-38)	In vitro inhibitory concentration required against HT-29 human colon cancer cells In vitro inhibitory concentration required against HT-29 human colon cancer cells	[PMID: 12617927]
HT-29	IC₅₀	0.012 μM Compound: SN-38	Antiproliferative activity against human HT29 cells after 96 hrs Antiproliferative activity against human HT29 cells after 96 hrs	[PMID: 18276141]
HT-29	IC₅₀	0.67 μM Compound: SN-38	Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
HT-29	IC₅₀	11.5 μM Compound: SN-38	Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
HT-29	IC₅₀	0.12 μM Compound: SN-38	Cytotoxicity against human HT-29 cells by SRB method Cytotoxicity against human HT-29 cells by SRB method	[PMID: 18986807]
HT-29	IC₅₀	0.17 μM Compound: 5, SN-38	Antitumor activity against human HT-29 cells by SRB method Antitumor activity against human HT-29 cells by SRB method	[PMID: 19541483]
HT-29	IC₅₀	0.0059 μM Compound: SN-38	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 21470864]
HT-29	IC₅₀	30 nM Compound: SN-38	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 23578545]
HT-29	IC₅₀	106.67 nM Compound: 5, SN-38	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 3 days by SRB assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 3 days by SRB assay	[PMID: 24529870]
HT-29	IC₅₀	18.54 nM Compound: SN-38	Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay	[PMID: 25835359]
HT-29	IC₅₀	0.054 μM Compound: SN-38	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
HT-29	IC₅₀	2.74 μM Compound: SN-38	Cytotoxicity against human HT-29 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28350997]
HT-29	IC₅₀	3.71 μM Compound: SN-38	Cytotoxicity against human HT-29 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28350997]
HT-29	IC₅₀	0.096 μM Compound: SN-38	Cytotoxicity against human HT-29 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
HT-29	IC₅₀	0.119 μM Compound: SN-38	Cytotoxicity against human HT-29 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
HT-29	IC₅₀	0.02 μM Compound: 1d; SN38	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
HT-29	IC₅₀	0.43 μM Compound: 2; SN38	Cytotoxicity against human HT-29 cells incubated for 48 hrs by SRB assay Cytotoxicity against human HT-29 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
Jurkat	IC₅₀	<1 μM Compound: SN-38	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
KB 3-1	IC₅₀	0.004 μM Compound: SN-38	Cytotoxicity against human KB3-1 cells after 4 days by MTT method Cytotoxicity against human KB3-1 cells after 4 days by MTT method	[PMID: 19303306]
KB-V1	IC₅₀	0.046 μM Compound: SN-38	Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method	[PMID: 19303306]
L02	IC₅₀	18 nM Compound: SN38	Cytotoxicity agains human HL7702 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxicity agains human HL7702 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
L1210	IC₅₀	8.9 nM Compound: 44	Inhibitory activity in mice bearing L1210 leukemia Inhibitory activity in mice bearing L1210 leukemia	[PMID: 1846923]
L1210	IC₅₀	0.04 μM Compound: SN-38	Cytotoxicity against mouse L1210 cells Cytotoxicity against mouse L1210 cells	[PMID: 23578545]
L1210	IC₅₀	8.9 nM Compound: 14; SN-38	Cytotoxicity against mouse L1210 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
LNCaP	GI₅₀	0.0122 μM Compound: SN-38	Growth inhibition of human LNCaP cells by Cell-titer96 assay Growth inhibition of human LNCaP cells by Cell-titer96 assay	[PMID: 33492141]
LoVo	IC₅₀	0.301 μM Compound: SN-38	Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
LOX IMVI	GI₅₀	5.3 nM Compound: 4; SN-38	Antiproliferative activity against human LOXIMVI cells after 48 hrs by SRB assay Antiproliferative activity against human LOXIMVI cells after 48 hrs by SRB assay	[PMID: 30553626]
MCF7	IC₅₀	0.37 μM Compound: SN-38	Antiproliferative activity against human MCF-7 breast cell line Antiproliferative activity against human MCF-7 breast cell line	[PMID: 10498216]
MCF7	IC₅₀	0.515 μM Compound: SN-38	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
MCF7	IC₅₀	<0.1 nM Compound: SN38	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 30169038]
MCF7	GI₅₀	3 nM Compound: 4; SN-38	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 30553626]
MCF7	IC₅₀	1.25 μM Compound: SN38	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30600208]
MCF7	IC₅₀	0.66 μM Compound: 1d; SN38	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
MCF7	IC₅₀	0.1 nM Compound: 14; SN-38	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
MDA-MB-231	IC₅₀	0.176 μM Compound: 5, SN-38	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 24529870]
MDA-MB-231	IC₅₀	1.97 μM Compound: SN-38	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
MDA-MB-231	GI₅₀	0.512 μM Compound: SN-38	Growth inhibition of human MDA-MB-231 cells by Cell-titer96 assay Growth inhibition of human MDA-MB-231 cells by Cell-titer96 assay	[PMID: 33492141]
MDA-MB-435	IC₅₀	5 nM Compound: SN-38	Inhibition against MDA-MB-435 S human breast cancer cells in the absence of albumin Inhibition against MDA-MB-435 S human breast cancer cells in the absence of albumin	[PMID: 11052802]
MDA-MB-435	IC₅₀	50 nM Compound: SN-38	Inhibition against MDA-MB-435 S human breast cancer cells in the presence of 30 mg/mL HSA Inhibition against MDA-MB-435 S human breast cancer cells in the presence of 30 mg/mL HSA	[PMID: 11052802]
MDCK-II	GI₅₀	0.139 μM Compound: SN-38	Cytotoxicity against wild-type MDCK-II cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against wild-type MDCK-II cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33454462]
MIA PaCa-2	IC₅₀	13 nM Compound: SN38	Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
MKN-28	GI₅₀	110 nM Compound: 4; SN-38	Antiproliferative activity against human MKN28 cells after 48 hrs by SRB assay Antiproliferative activity against human MKN28 cells after 48 hrs by SRB assay	[PMID: 30553626]
MKN-45	IC₅₀	8 nM Compound: SN-38	In Vitro cytotoxicity against human stomach cancer cell line (MKN45) In Vitro cytotoxicity against human stomach cancer cell line (MKN45)	[PMID: 11334569]
MRC5	IC₅₀	15.3 μM Compound: SN-38	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
NCI-H128	IC₅₀	6 nM Compound: SN-38	In Vitro cytotoxicity against human lung cancer cell line (H128) In Vitro cytotoxicity against human lung cancer cell line (H128)	[PMID: 11334569]
NCI-H1975	IC₅₀	0.81 μM Compound: SN-38	Cytotoxicity against human NCI-H1975 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
NCI-H226	GI₅₀	0.277 μM Compound: SN-38	Growth inhibition of human NCI-H226 cells by Cell-titer96 assay Growth inhibition of human NCI-H226 cells by Cell-titer96 assay	[PMID: 33492141]
NCI-H460	IC₅₀	0.21 μM Compound: SN-38	In vitro inhibitory concentration against human lung large cell carcinoma cell line, H460 (after 1 hour exposure) In vitro inhibitory concentration against human lung large cell carcinoma cell line, H460 (after 1 hour exposure)	[PMID: 15501036]
NCI-H460	IC₅₀	0.08 μM Compound: SN-38	Inhibition of human H460 cell growth Inhibition of human H460 cell growth	[PMID: 16913706]
NCI-H460	IC₅₀	0.22 μM Compound: SN-38	Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
NCI-H460	IC₅₀	0.22 μM Compound: SN-38	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 18434153]
NCI-H460	IC₅₀	3.3 nM Compound: SN-38	Antiproliferative activity against human NCI-H460 cells after 3 days Antiproliferative activity against human NCI-H460 cells after 3 days	[PMID: 19254843]
NCI-H460	IC₅₀	0.13 μM Compound: SN-38	Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium	[PMID: 19530720]
NCI-H460	IC₅₀	0.05 μM Compound: SN-38	Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28350997]
NCI-H460	IC₅₀	0.06 μM Compound: SN-38	Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28350997]
NCI-H460	IC₅₀	0.047 μM Compound: SN-38	Cytotoxicity against human NCI-H460 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
NCI-H460	IC₅₀	0.05 μM Compound: SN-38	Cytotoxicity against human NCI-H460 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
NCI-H522	GI₅₀	3.7 nM Compound: 4; SN-38	Antiproliferative activity against human NCI-H522 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-H522 cells after 48 hrs by SRB assay	[PMID: 30553626]
P388	IC₅₀	6.93 ng/mL Compound: 5	Tested in vitro for the inhibition of P388 (mouse leukemia) cell line by MTT assay; 1.95-6.93 ng/mL Tested in vitro for the inhibition of P388 (mouse leukemia) cell line by MTT assay; 1.95-6.93 ng/mL	[PMID: 7932525]
P388	IC₅₀	1.44 ng/mL Compound: 5 (SN-38)	In vitro antitumor activity against P388 (murine leukemia) cells. In vitro antitumor activity against P388 (murine leukemia) cells.	[PMID: 9632364]
PC-3	IC₅₀	0.0026 μM Compound: 3, SN38	Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
PC-6	IC₅₀	0.43 nM Compound: SN-38	Antiproliferative activity against human PC6 cells carrying pRC after 6 days Antiproliferative activity against human PC6 cells carrying pRC after 6 days	[PMID: 19254843]
PC-6	IC₅₀	5.1 nM Compound: SN-38	Antiproliferative activity against human PC6 expressing BCRP cells after 6 days Antiproliferative activity against human PC6 expressing BCRP cells after 6 days	[PMID: 19254843]
QG-56	IC₅₀	2.8 nM Compound: SN-38	Antiproliferative activity against human QG56 cells after 3 days Antiproliferative activity against human QG56 cells after 3 days	[PMID: 19254843]
QG-56	IC₅₀	3.17 ng/mL Compound: 5	Tested in vitro for the inhibition of QG-56 (human lung squamous cell carcinoma) cell line by MTT assay Tested in vitro for the inhibition of QG-56 (human lung squamous cell carcinoma) cell line by MTT assay	[PMID: 7932525]
QG-56	IC₅₀	0.9 ng/mL Compound: 5 (SN-38)	In vitro antitumor activity against QG-56 (human lung cancer) cells. In vitro antitumor activity against QG-56 (human lung cancer) cells.	[PMID: 9632364]
Raji	IC₅₀	0.005 μM Compound: SN-38	Cytotoxicity against human Raji assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human Raji assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
RPMI-7951	IC₅₀	0.26 μM Compound: SN 38	Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
SAOS-2	IC₅₀	176 nM Compound: SN-38	TP_TRANSPORTER: drug resistance(Imatinib mesylate) in BCRP-expressing SaoS2 cells TP_TRANSPORTER: drug resistance(Imatinib mesylate) in BCRP-expressing SaoS2 cells	[PMID: 15059881]
SiHa	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against FR-positive human SiHa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against FR-positive human SiHa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
SJRH30	GI₅₀	0.0093 μM Compound: SN-38	Growth inhibition of human SJRH30 cells by Cell-titer96 assay Growth inhibition of human SJRH30 cells by Cell-titer96 assay	[PMID: 33492141]
SK-BR-3	IC₅₀	4 nM Compound: SN-38	In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3) In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3)	[PMID: 11334569]
SK-HEP1	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against FR-positive human SKHEP1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against FR-positive human SKHEP1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
SK-MEL-24	IC₅₀	0.48 μM Compound: SN 38	Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
SK-OV-3	IC₅₀	0.72 μM Compound: SN-38	Antiproliferative activity against human SKOV-3 ovarian cell line Antiproliferative activity against human SKOV-3 ovarian cell line	[PMID: 10498216]
SK-OV-3	IC₅₀	11 nM Compound: SN-38	In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3) In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3)	[PMID: 11334569]
SK-OV-3	GI₅₀	23 nM Compound: 4; SN-38	Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 30553626]
TE-8	IC₅₀	<1 μM Compound: SN-38	Cytotoxicity against human TE8 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human TE8 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
U-251	IC₅₀	0.021 μM Compound: SN-38	Cytotoxicity against human U251 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human U251 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
U-251	GI₅₀	2.8 nM Compound: 4; SN-38	Antiproliferative activity against human U251 cells after 48 hrs by SRB assay Antiproliferative activity against human U251 cells after 48 hrs by SRB assay	[PMID: 30553626]
U-87MG ATCC	IC₅₀	0.03 μM Compound: SN-38	Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
WiDr	IC₅₀	14 nM Compound: SN-38	In Vitro cytotoxicity against human colon cancer cell line (WiDr) In Vitro cytotoxicity against human colon cancer cell line (WiDr)	[PMID: 11334569]

In Vitro

The IC₅₀ values for LoVo, HCT116, and HT29 cell lines is 20 nM, 50 nM, 130 nM, respectively. In all three SN-38 resistant cell lines Top1 activity is maintained in the presence of high concentrations of SN-38^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SN-38, the active and toxic metabolite of the anticancer prodrug Irinotecan. At 30 minutes after administration, Irinotecan plasma concentrations in Slco1a/1b(-/-) mice are 1.9-fold higher than in the wild-type mice (1.89 vs. 1.01 μM, respectively), whereas SN-38 plasma concentrations of Slco1a/1b(-/-) mice are 8-fold higher compare with wild-type mice (0.4 μg/mL vs. 0.05 μg/mL, respectively). Overall plasma exposure [AUC_(5-240)] of Irinotecan is 1.7-fold higher in Oatp1a/1b knockout mice versus wild-type mice (209.8±6.7 vs. 120.9±4.4 μM/min; P<0.01), and 2.9-fold higher for SN-38 (50±2.9 vs. 12±2 μM/min; P<0.001)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 86639-52-3
Appearance Solid
Molecular Weight 392.40
Formel C₂₂H₂₀N₂O₅
Color Off-white to yellow
SMILES

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C2)=O
Synonyms

7-Ethyl-10-hydroxycamptothecin
Structure Classification
- Alkaloids
- Quinoline Alkaloids
Initial Source
- Plants
- Labiatae
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (79)

All OthersWBFlow CytometryCell Proliferation/Viability AssayRT-PCR

Sort by:

Journal Impact Factor

Nat Med

Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. [Abstract]

2024 Mar;30(3):749-761. PMID: 38287168
Nature

TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. [Abstract]

2024 Apr;628(8007):416-423. PMID: 38538786
Nature

Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells. [Abstract]

2022 Nov;611(7936):603-613. PMID: 36352230
Nat Cancer

Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. [Abstract]

2022 Sep;3(9):1052-1070. PMID: 35773527
Cancer Res

Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality. [Abstract]

2023 Dec 15;83(24):4015-4029. PMID: 37987734
Nat Commun

Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors. [Abstract]

2025 May 23;16(1):4793. PMID: 40410143
Nat Commun

Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma. [Abstract]

2024 Jun 21;15(1):5292. PMID: 38906855

SN-38 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]

Phospho-profiling using control and SN-38-treated (1 μM for 24 h) Ewing sarcoma MHH-ES-1 cell lysate. The right is quantifications of the phospho-profiling signals.

SN-38 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]

Immunoblot (IB) analysis of whole cell lysates (WCL) from A673 cells or MHH-ES-1 cellstreated with indicated doses of SN-38 for 24 h. SN-38 treatment increased Akt-pT308 and ERK-p42/p44 signals in a dose-dependent manner in A673, MHH-ES-1

SN-38 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]

FACS analysis by Annexin V to directly measure PtdSer levels confirmed that both SN-38 (1 μM for 24 h) and etoposide treatments significantly increased PtdSer levels.

SN-38 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]

Cell viability assays using MHH-ES-1 cells pre-treated with normal media or GAS6-conditioned media for 24 h, followed by treatment by indicated doses of SN-38 for 72 h.

SN-38 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]

SN-38 (1 μM, 24h) treated MHH-ES-1 cells significantly enhanced GAS6 binding to SB1 and SB3.
Acta Pharm Sin B

2026 May 19.
J Extracell Vesicles

Analysis of extracellular vesicle DNA at the single-vesicle level by nano-flow cytometry. [Abstract]

2022 Apr;11(4):e12206. PMID: 35373518
Adv Sci (Weinh)

Loss of VMP1 Impairs Tight Junction Recycling and Aggravates Intestinal Barrier Dysfunction in Inflammatory Bowel Disease. [Abstract]

2026 May;13(25):e21681. PMID: 41757559
Adv Sci (Weinh)

Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy. [Abstract]

2025 Oct 24:e06552. PMID: 41133986
Adv Sci (Weinh)

A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer. [Abstract]

2021 Nov;8(21):e2101936. PMID: 34605226
Chem Eng J

2025 Jun 6.
Biomaterials

A single-chain fab derived drug conjugate for HER2 specific delivery. [Abstract]

2024 Sep 2:313:122798. PMID: 39244823
J Exp Clin Cancer Res

Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma. [Abstract]

2023 Apr 3;42(1):79. PMID: 37013646
Carbohydr Polym

A dermatan sulfate-functionalized biomimetic nanocarrier for melanoma targeted chemotherapy. [Abstract]

2020 May 1;235:115983. PMID: 32122513
J Control Release

Combined nanomedicines targeting colorectal cancer stem cells and cancer cells. [Abstract]

2020 Oct 10;326:387-395. PMID: 32702392
EBioMedicine

A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation. [Abstract]

2023 Jun:92:104594. PMID: 37167784
Cell Rep Med

Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling. [Abstract]

2025 Oct 30:102423. PMID: 41172996
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cancer Lett

Tumor-derived CCL5 recruits CCR1+ macrophages to suppress apoptosis and drive proliferation in duodenal adenocarcinoma. [Abstract]

2025 Sep 25:634:218064. PMID: 41015267
Cell Death Dis

2026 Apr 3;17(1):449. PMID: 41932868
Adv Healthc Mater

Cascade-Responsive Nanoprodrug Disrupts Immune-Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy. [Abstract]

2025 Apr;14(11):e2500176. PMID: 40079115
Cell Death Dis

Golgi dispersal in cancer stem cells promotes chemoresistance of colorectal cancer via the Golgi stress response. [Abstract]

2024 Jun 15;15(6):417. PMID: 38879509
Acta Pharmacol Sin

HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade. [Abstract]

2025 Sep 10. PMID: 40931042
NPJ Breast Cancer

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. [Abstract]

2023 Aug 11;9(1):66. PMID: 37567892
J Med Chem

Novel Aptamer-Drug Conjugate for Targeted Therapy in Triple-Negative Breast Cancer. [Abstract]

2025 Jul 20. PMID: 40685636
Int J Nanomedicine

Salinomycin-Loaded Small-Molecule Nanoprodrugs Enhance Anticancer Activity in Hepatocellular Carcinoma. [Abstract]

2020 Sep 15;15:6839-6854. PMID: 32982236
Cancer Cell Int

Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis. [Abstract]

2025 Mar 26;25(1):115. PMID: 40140870
Biochem Pharmacol

Treatment with S-adenosylmethionine ameliorates irinotecan-induced intestinal barrier dysfunction and intestinal microbial disorder in mice. [Abstract]

2023 Oct:216:115752. PMID: 37634598
Mol Cancer Ther

The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma. [Abstract]

2025 Jun 13. PMID: 40509933
Drug Deliv Transl Res

Biomimetic modification of macrophage membrane-coated prussian blue nanoparticles loaded with SN-38 to treat colorectal cancer by photothermal-chemotherapy. [Abstract]

2025 May;15(5):1525-1539. PMID: 39251553
Biomacromolecules

Targeted Drug Delivery Using a Plug-to-Direct Antibody-Nanogel Conjugate. [Abstract]

2023 Feb 13;24(2):849-857. PMID: 36639133
Chem Biol Interact

Inhibition of UGT1A1*1 and UGT1A1*6 catalyzed glucuronidation of SN-38 by silybins. [Abstract]

2022 Dec 1:368:110248. PMID: 36343684
Mar Life Sci Technol

Nitrobenzoyl-insulicolide A: a novel dinitrobenzoyl sesquiterpenoid, induces autophagic cell death in small cell lung cancer cells. [Abstract]

2025 May 12;7(4):949-961. PMID: 41322261
Int J Pharm

Oligoelectrolyte-mediated, pH-triggered release of hydrophobic drugs from non-responsive micelles: Influence of oligo(2-vinyl pyridine)-loading on drug-loading, release and cytotoxicity. [Abstract]

2024 Jun 24:124368. PMID: 38925236
Int J Pharm

Inhibition of colorectal cancer-associated fibroblasts by lipid nanocapsules loaded with acriflavine or paclitaxel. [Abstract]

2020 Jun 30:584:119337. PMID: 32371002
Int J Pharm

Combinational drug-loaded lipid nanocapsules for the treatment of cancer. [Abstract]

2019 Oct 5:569:118588. PMID: 31377406
Commun Biol

3D collagen high-throughput screen identifies drugs that induce epithelial polarity and enhance chemotherapy response in colorectal cancer. [Abstract]

2025 Aug 22;8(1):1261. PMID: 40847193
Commun Biol

Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. [Abstract]

2024 Dec 3;7(1):1612. PMID: 39627437
Drug Des Devel Ther

Investigating the Impact of SN-38 on Mouse Brain Metabolism Based on Metabolomics. [Abstract]

2024 Jun 20:18:2435-2447. PMID: 38915864
Life Sci

The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice. [Abstract]

2019 Aug 15:231:116529. PMID: 31173781
Int J Mol Sci

Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy. [Abstract]

2025 Jan 8;26(2):474. PMID: 39859189
Int J Oncol

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line. [Abstract]

2022 Nov;61(5):139. PMID: 36169178
J Drug Deliv Sci Technol

2021, 102596.
Molecules

Evaluation of In Vivo Prepared Albumin-Drug Conjugate Using Immunoprecipitation Linked LC-MS Assay and Its Application to Mouse Pharmacokinetic Study. [Abstract]

2023 Apr 4;28(7):3223. PMID: 37049985
Molecules

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. [Abstract]

2020 Jun 4;25(11):2614. PMID: 32512790
Cancers (Basel)

Organoid Level Assessments of Human Primary and Metastatic Colorectal Cancer-Derived Organoids Predict Response to Chemotherapy and Chemoradiation. [Abstract]

2026 May 13;18(10):1587. PMID: 42192947
Cancers (Basel)

FL118 Enhances Therapeutic Efficacy in Colorectal Cancer by Inhibiting the Homologous Recombination Repair Pathway through Survivin-RAD51 Downregulation. [Abstract]

2024 Oct 3;16(19):3385. PMID: 39410005
Cancers (Basel)

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus. [Abstract]

2022 Sep 30;14(19):4789. PMID: 36230712
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Sci Rep

Targeting colorectal cancer with pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides: comprehensive in vitro evaluation. [Abstract]

2026 May 31. PMID: 42225755
Sci Rep

Comprehensive metabolomics study identifies SN-38 organ specific toxicity in mice. [Abstract]

2025 May 12;15(1):16405. PMID: 40355563
J Pharm Biomed Anal

Development and optimization of a high-throughput LC-MS/MS method for the simultaneous determination of Exatecan and its Cathepsin B-sensitive prodrug, and ARV-825 in rat plasma: Application to pharmacokinetic study. [Abstract]

2025 Jun 15:258:116746. PMID: 39955884
New J Chem

2025 Sep 15.
New J Chem

2025 Jan 06.
Pediatr Blood Cancer

PD-L1 Expression is Mediated by microRNA Processing, Wnt/β-Catenin Signaling, and Chemotherapy in Wilms Tumor. [Abstract]

2025 Sep;72(9):e31852. PMID: 40512079
Oncol Lett

Pan‑cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy. [Abstract]

2024 Jul 19;28(3):444. PMID: 39091583
Anticancer Res

Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer. [Abstract]

2024 Jan;44(1):31-35. PMID: 38159986
SSRN

2026 Jun 8.
bioRxiv

2026 May 27.
bioRxiv

Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention. [Abstract]

2026 Apr 15:2026.04.13.718209. PMID: 42039381
bioRxiv

2026 Apr 7.
medRxiv

2026 Apr 18.
bioRxiv

2025 Sep 21.
SSRN

2025 Jul 7.
Patent

US20250152731A1.
Indiana University Indianapolis

2025.
SSRN

2025 Mar 4.
Research Square Preprint

2024 Nov 06.
bioRxiv

PD-L1 expression is mediated by microRNA processing, Wnt/β-catenin signaling, and chemotherapy in Wilms tumor. [Abstract]

2024 Dec 3:2024.11.29.626084. PMID: 39677784
Patent

US20240197907A1.
Research Square Preprint

2023 Dec 4.
Research Square Preprint

2023 Oct 12.
bioRxiv

2023 Feb 28.
Patent

US20230036256A1.
Patent

US20220047595A1.
Université de Genève

2020 Sep.
Patent

US20190343828 A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (63.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5484 mL

12.7421 mL

25.4842 mL

5 mM

0.5097 mL

2.5484 mL

5.0968 mL

10 mM

0.2548 mL

1.2742 mL

2.5484 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (6.37 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (5.30 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (5.30 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

In vitro SN-38 sensitivity is determined using the MTT assay. Cells are seeded in 96-well plates, and a range of SN-38 concentrations is added the following day. Following 48 h of drug exposure, the medium is discarded and the plates are incubated with medium containing MTT (0.5 mg/mL) for 3 h. Acidified (0.02 M HCl) sodium dodecyl sulphate (20 %) is added to dissolve the formed formazan. Optical density at 570 nm (and 670 nm for background) is measured, and the cell viability is calculated in percent compared to untreated cells. Experiments are repeated three times and the mean IC₅₀ value ± standard deviation is determined. Relative resistance for each resistant cell line is calculated by dividing the mean IC₅₀ value of the resistant cell line by the mean IC₅₀ value of the corresponding parental cell line^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice^[3]
Female wild-type, Slco1a/1b(−/−)(Oatp1a/1b knockout), Slco1a/1b(−/−);1B1(tg), and Slco1a/1b(−/−);1B3(tg) (liver-specific OATP1B1 and OATP1B3 humanized transgenic) mice of comparable genetic background (>99% FVB) between 8 and 14 weeks of age are used. Irinotecan (20 mg/mL in water-based solution containing NaOH, lactic acid, and sorbitol) is diluted with saline (to 2 mg/mL) for administration of 10 mg/kg; 5 μL/g bodyweight are administered intravenously to mice. SN-38 is dissolved in DMSO (1 mg/mL) and 1 μL/g body weight is administered intravenously to mice to achieve a dosage of 1 mg/kg. The experiments are terminated by isoflurane anaesthesia, heparin-blood sampling by cardiac puncture followed by cervical dislocation and tissue collection. Blood samples are centrifuged at 5,200 × g for 5 minutes at 4°C and plasma is collected and stored at −30°C until analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19(6):1493-8. [Content Brief]

[2]. Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56. [Content Brief]

[3]. Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187-4191. [Content Brief]

[4]. Aaron T Jacobs, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022 Oct:204:115209. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5484 mL	12.7421 mL	25.4842 mL	63.7105 mL
	5 mM	0.5097 mL	2.5484 mL	5.0968 mL	12.7421 mL
	10 mM	0.2548 mL	1.2742 mL	2.5484 mL	6.3711 mL
	15 mM	0.1699 mL	0.8495 mL	1.6989 mL	4.2474 mL
	20 mM	0.1274 mL	0.6371 mL	1.2742 mL	3.1855 mL
	25 mM	0.1019 mL	0.5097 mL	1.0194 mL	2.5484 mL
	30 mM	0.0849 mL	0.4247 mL	0.8495 mL	2.1237 mL
	40 mM	0.0637 mL	0.3186 mL	0.6371 mL	1.5928 mL
	50 mM	0.0510 mL	0.2548 mL	0.5097 mL	1.2742 mL
	60 mM	0.0425 mL	0.2124 mL	0.4247 mL	1.0618 mL

Keywords

SN-38

79 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SN-38

Toxins for Antibody-Drug Conjugate Research Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Traditional Chinese Medicine Active Compound Library

Alkaloids Library

Anti-Lung Cancer Compound Library

Drug Metabolite Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) SN-38

Alle Topoisomerase Isoform-spezifische Produkte anzeigen

Alle ADC Payloads Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (79)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SN-38 Related Classifications

HY-13704 Related Classifications